Compare Summit Therapeutics Inc (SMMT) vs Roundhill S&P 500 0DTE Covered Call Strategy ETF (XDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? Summit Therapeutics Inc trades at $17.54 (market cap $13.71B), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $38.7 (market cap $330.98M). The key difference: Summit Therapeutics Inc is far larger — about 41.4× Roundhill S&P 500 0DTE Covered Call Strategy ETF's market cap, and Roundhill S&P 500 0DTE Covered Call Strategy ETF is more actively traded (194,030 versus 6,173,057). Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Roundhill S&P 500 0DTE Covered Call Strategy ETF for 54 Days on average.
| SMMT | XDTE | |
|---|---|---|
Market Cap | $13.71B | $330.98M |
Volume | 6,173,057 | 194,030 |
Sector | Health | Income / Options Overlay |
52-Week High | $26.38 | $44.76 |
52-Week Low | $12.43 | $36.00 |
Typical Hold Time | 16 Days | 54 Days |
Enterprise Value | $13.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Roundhill S&P 500 0DTE Covered Call Strategy ETF
XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →
